Randomised, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)

Type: Interventional

Site and lead:

  • Oxford Road Campus: Dr Jonathan Bannard-Smith
  • Wythenshawe Hospital: Dr Peter Alexander

Patient group: COVID-19 patients in ICU


  • Lopinavir/ritonavir
  • Anakinra
  • Convalescent Plasma

Funder: European Commission

Sponsor: University Medical Centre Utrecht (Netherlands)

More about REMAP-CAP

The primary purpose of this study is to generate evidence that can be applied during the coronavirus pandemic in order to reduce deaths, Intensive Care Unit (ICU) use, and morbidity in severely ill patients with COVID-19 infection.

It is a fully adaptive, platform trial, meaning several different treatments can be tested at the same time under one ‘platform’ – and more treatments can be added as new evidence emerges.